Multispecific Polypeptide with Cleavable Linker for Constrained CD3 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic antibodies that target CD3 for therapeutic and diagnostic purposes often lack specificity and efficiency, as they can activate T-cells systemically, leading to off-target effects and reduced efficacy.
Innovation Solution
Development of multispecific polypeptides with constrained CD3 binding, featuring a specific structural arrangement where the Fc region is positioned N-terminal to the CD3-binding region, coupled by a cleavable linker, allowing targeted binding only when antigen-binding domains engage their cognate antigens, thereby reducing systemic activation and enhancing localization to tumor sites.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If therapeutic antibodies directly engage CD3 for T-cell activation, then T-cell activation occurs, but systemic activation leads to off-target effects and reduced efficacy
Solution Approach 1:
The antibody is divided into two separate components: an Fc component and a TAA-binding component, connected by a cleavable linker. The Fc component contains the CD3-binding region, while the TAA-binding component targets tumor-associated antigens. This segmentation allows the antibody to remain inactive during circulation and only activate CD3 upon reaching the tumor site, thereby eliminating systemic off-target effects while maintaining reliable CD3 engagement at the target site.
Solution Approach 2:
The antibody is designed to undergo preliminary action through proteolytic cleavage of the linker at the tumor site before CD3 activation occurs. The cleavable linker is positioned such that proteases present in the tumor microenvironment can cleave it, releasing the Fc component to bind CD3. This preliminary cleavage action ensures that CD3 activation only occurs after the antibody has reached the tumor site, preventing premature systemic activation and off-target effects.
2Reliability
If multisspecific polypeptides are designed with cleavable linkers for targeted activation, then localization to tumor sites is enhanced, but structural complexity increases
Solution Approach 1:
The Fc component is designed to serve multiple functions: it provides the CD3-binding capability, contains the cleavable linker for targeted activation, and maintains the necessary structural framework for T-cell engagement. By making the Fc component multi-functional, the invention reduces the need for additional separate elements, thereby managing structural complexity while achieving reliable targeted binding specificity.
Solution Approach 2:
The cleavable linker serves as an intermediary element that connects the Fc component and the TAA-binding component. This intermediary structure enables controlled activation by proteases at the tumor site without requiring complex additional mechanisms. The linker's simple yet effective design allows targeted activation while keeping the overall structural arrangement manageable, balancing reliability of targeted binding with acceptable structural complexity.
Data Source
AI summary
The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, results in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.